« Return to News | Awards & Advancement

Zafgen receives $33 million in Series C financing

Friday, July 8, 2011 01:00 PM

Zafgen, a pharmaceutical company, announced the closing of a $33 million Series C financing led by the existing investor syndicate, including Atlas Venture and Third Rock Ventures. The financing will be used to support development of Zafgen's pipeline and to advance its lead methionine aminopeptidase 2 (MetAP2) inhibitor for the treatment of severe obesity into phase II clinical studies.

"This Series C funding provides further validation of the promise of MetAP2 inhibitor treatment as a pharmacological alternative to bariatric surgery in the treatment of severe obesity and is a testament to the progress we have made in advancing our drug development efforts," said Thomas Hughes, Ph.D., president and CEO of Zafgen.

Research continues to show that obese and lean individuals metabolize fat differently. Studies indicate that once a person becomes obese, the body undergoes certain metabolic changes and is "programmed" to make and store more fat.

"Zafgen has a unique approach to tackling obesity by targeting imbalances in fat metabolism through MetAP2 inhibition. The company's recent phase Ib study results showed that, in addition to rapid weight loss averaging 1kg per week, a significant improvement in cardiovascular risk markers was seen in severely obese subjects. These results further demonstrate that Zafgen has the potential to bring to market a promising new drug for the treatment of severe obesity,” said Kevin Starr, partner in Third Rock Ventures.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.